Lymphoma Clinical Trial
Official title:
A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma
Verified date | May 2018 |
Source | AIDS Malignancy Consortium |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
such as rituximab, can block cancer growth in different ways. Some find cancer cells and help
kill them or carry cancer-killing substances to them. Others interfere with the ability of
cancer cells to grow and spread. Giving combination chemotherapy together with rituximab may
kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving combination chemotherapy together
with rituximab works in treating patients with newly diagnosed AIDS-related B-cell
non-Hodgkin's lymphoma.
Status | Completed |
Enrollment | 43 |
Est. completion date | September 2011 |
Est. primary completion date | September 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed AIDS-related B-cell non-Hodgkin's lymphoma (NHL), including any of the following subtypes: - Grade III follicular large cell lymphoma - Diffuse large B-cell lymphoma - Immunoblastic lymphoma - Plasmablastic lymphoma - Primary effusion lymphoma - Previously untreated disease - Any stage disease - CD20 positive disease - Must have documented HIV infection - Documentation may be by serology (enzyme-linked immunosorbent assay, western blot), culture, or quantitative polymerase chain reaction or branched DNA assays - Prior documentation of HIV seropositivity allowed - Measurable or nonmeasurable disease - Currently receiving effective highly active anti-retroviral therapy - No primary CNS lymphoma, including parenchymal brain or spinal cord lymphoma - No presence of leptomeningeal disease (positive cerebrospinal fluid for lymphoma) or presence of metastatic disease to brain, in terms of any mass lesion PATIENT CHARACTERISTICS: - ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100% - Life expectancy = 2 months - Absolute granulocyte (neutrophil) count = 1,000/mm³ (unless secondary to lymphomatous involvement of bone marrow) - Platelet count = 75,000/mm³ (unless secondary to lymphomatous involvement of bone marrow or due to HIV-related thrombocytopenia) - Bilirubin = 2.0 mg/dL (unless elevated secondary to lymphomatous involvement of liver or biliary system or due to other HIV medications [e.g., indinavir, tenofavir, or atazanavir]) - SGOT = 5 times upper limit of normal - Creatinine = 2.0 mg/dL OR creatinine clearance = 60 mL/min (unless secondary to renal involvement by lymphoma) - LVEF normal by MUGA or echocardiogram - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after completion of study treatment - No other malignancy, except nonmelanoma skin cancer, carcinoma in situ of the cervix, or Kaposi's sarcoma that does not require systemic therapy - No serious, ongoing, nonmalignant disease or infection that would preclude study compliance, in the opinion of the investigator - No history of cutaneous or mucocutaneous reactions, or diseases in the past, due to any cause, severe enough to cause hospitalization or an inability to eat or drink for = 2 days - No acute, intercurrent infection that would preclude study treatment - Patients with Mycobacterium avium are eligible - No cardiovascular problems, including any of the following: - Myocardial infarction within the past 6 months - New York Heart Association class II-IV heart failure - Uncontrolled angina - Severe uncontrolled ventricular arrhythmias - Clinically significant pericardial disease - ECG evidence of acute ischemic or active conduction system abnormalities. - No shortness of breath at rest - Arterial PO_2 = 70 or pulse oximeter-derived O_2 saturation = 94% on room air (unless due to lymphomatous involvement of the lungs) - Able to comply with study and provide adequate informed consent PRIOR CONCURRENT THERAPY: - See Disease Characteristics - At least 4 weeks since prior major surgery (except diagnostic surgery) - At least 12 months since prior rituximab unless it was only given for indications other than the treatment of aggressive lymphoma - No prior cytotoxic chemotherapy or radiotherapy for this lymphoma - Concurrent radiotherapy, with or without steroids, for emergency conditions secondary to lymphoma (i.e., CNS tumor or cord compression) allowed - No zidovudine or zidovudine-containing regimen (including Combivir® or Trizivir®) during and for 2 months after completion of chemotherapy - Concurrent erythropoietin or filgrastim (G-CSF) allowed - Growth factor therapy must be discontinued = 24 hours prior to study entry |
Country | Name | City | State |
---|---|---|---|
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Boston University Cancer Research Center | Boston | Massachusetts |
United States | Albert Einstein Cancer Center at Albert Einstein College of Medicine | Bronx | New York |
United States | Robert H. Lurie Comprehensive Cancer Center at Northwestern University | Chicago | Illinois |
United States | Case Comprehensive Cancer Center | Cleveland | Ohio |
United States | Rebecca and John Moores UCSD Cancer Center | La Jolla | California |
United States | UCLA Clinical AIDS Research and Education (CARE) Center | Los Angeles | California |
United States | USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles | California |
United States | University of Miami Sylvester Comprehensive Cancer Center - Miami | Miami | Florida |
United States | Ochsner Cancer Institute at Ochsner Clinic Foundation | New Orleans | Louisiana |
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
United States | Joan Karnell Cancer Center at Pennsylvania Hospital | Philadelphia | Pennsylvania |
United States | Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | Saint Louis | Missouri |
United States | Virginia Mason Medical Center | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
AIDS Malignancy Consortium | National Cancer Institute (NCI), The EMMES Corporation |
United States,
Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI . | After cycles 2, 4, 6, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation | ||
Primary | Duration of Response | After cycles 2, 4, 6, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation | ||
Primary | Median Survival Time | After cycles 2, 4, 6, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation | ||
Primary | Rate of Bacterial, Fungal, and Opportunistic Infections | After every cycle of treatment, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation | ||
Secondary | Relationship Between MDR-1 Expression and Response to Treatment | Baseline | ||
Secondary | Relationship Between Response and Survival and BCL-2 Expression in Tumor Tissue | Baseline, after cycles 4 and 6, 1 month after treatment discontinuation | ||
Secondary | Relationship Between Development of Bacterial, Fungal, and/or Opportunistic Infections and Baseline CD4 Lymphocyte Count, HIV-1 RNA Level, and Quantitative Immunoglobin Level, or Changes in Quantitative Immunoglobin Levels Over Time | After every cycle of treatment, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation | ||
Secondary | Mortality and Cause of Death | At any time through the third year after treatment discontinuation | ||
Secondary | Event-free Survival at 1 Year | 1 year post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |